Progress and challenges in the adjuvant treatment of stage II and III colon cancersYu Jo Chua
The Canberra Hospital, Australian Capital Territory, Australia
Expert Rev Anticancer Ther 8:595-604. 2008
....
Recent advances in management of small-cell lung cancerYu Jo Chua
Medical Oncology Unit, The Canberra Hospital, P.O. Box 11, Woden, ACT 2606, Australia
Cancer Treat Rev 30:521-43. 2004
..The future of SCLC treatment may however lie with molecularly targeted therapies, such as antiangiogenesis agents and signal transduction inhibitors, which are being studied at present...
- Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer
Yu Jo Chua
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
Clin Colorectal Cancer 5:S81-8. 2005
..This article reviews the recent evidence supporting the combination of these anti-EGFR agents with the cytotoxic chemotherapeutic agent irinotecan...
- Pharmacotherapy for oesophagogastric cancer
Christopher Jackson
Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, London and Surrey, United Kingdom
Drugs 67:2539-56. 2007
..We examine areas of current research and highlight future therapeutic directions...
- Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham
Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
N Engl J Med 355:11-20. 2006
..We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among patients with potentially curable gastric cancer...
- East meets west in the treatment of gastric cancer
David Cunningham
N Engl J Med 357:1863-5. 2007
- The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice
Yu Jo Chua
Ann Surg Oncol 14:2687-90. 2007
- Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker
Diletta Bianchini
Department of Medicine, Royal Marsden Hospital, Down s Road, Sutton, Surrey, SM2 5PT UK
Clin Colorectal Cancer 7:33-43. 2008
..This review aims to summarize and update the current knowledge of the clinical presentation, predictive and prognostic value, and the management of EGFRI-related skin toxicity...
- Current treatment strategies in elderly patients with metastatic colorectal cancer
Hendrik Tobias Arkenau
Department of Medical Oncology, Royal Marsden Hospital London and Sutton, Surrey, United Kingdom
Clin Colorectal Cancer 6:508-15. 2007
..This article reviews the development of treatment for elderly patients with metastatic CRC, from single-agent fluoropyrimidines to combination therapies...
- Adjuvant treatment for resectable pancreatic cancer
Yu Jo Chua
Department of Medicine, Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom
J Clin Oncol 23:4532-7. 2005
..The optimal chemotherapy regimen for use as adjuvant treatment is the subject of ongoing trials. Other strategies which should be explored include neoadjuvant treatment and the incorporation of novel targeted agents into management...
- Neoadjuvant treatment of unresectable liver metastases from colorectal cancer
Yu Jo Chua
Department of Medicine, Royal Marsden Hospital, Surrey and London, United Kingdom
Clin Colorectal Cancer 5:405-12. 2006
....
- Chemotherapy for advanced pancreatic cancer
Yu Jo Chua
Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
Best Pract Res Clin Gastroenterol 20:327-48. 2006
..This article will review and discuss the clinical trials of chemotherapy for this disease, including the more recent trials, which have included the novel targeted agents...
- Panitumumab
Yu Jo Chua
Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
Drugs Today (Barc) 42:711-9. 2006
..Clinical trial results in colorectal cancer, in which the development of this agent is most advanced, will also be discussed, as will the rash associated with treatment...
